Found: 16
Select item for more details and to access through your institution.
Novel meriolin derivatives potently inhibit cell cycle progression and transcription in leukemia and lymphoma cells via inhibition of cyclin-dependent kinases (CDKs).
- Published in:
- Cell Death Discovery, 2024, v. 10, n. 1, p. 1, doi. 10.1038/s41420-024-02056-6
- By:
- Publication type:
- Article
Novel meriolin derivatives activate the mitochondrial apoptosis pathway in the presence of antiapoptotic Bcl-2.
- Published in:
- Cell Death Discovery, 2024, v. 10, n. 1, p. 1, doi. 10.1038/s41420-024-01901-y
- By:
- Publication type:
- Article
The Mycotoxin Beauvericin Exhibits Immunostimulatory Effects on Dendritic Cells via Activating the TLR4 Signaling Pathway.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.856230
- By:
- Publication type:
- Article
The mycotoxin viriditoxin induces leukemia- and lymphoma-specific apoptosis by targeting mitochondrial metabolism.
- Published in:
- Cell Death & Disease, 2022, v. 13, n. 11, p. 1, doi. 10.1038/s41419-022-05356-w
- By:
- Publication type:
- Article
Oxa Analogues of Nexturastat A Demonstrate Improved HDAC6 Selectivity and Superior Antileukaemia Activity.
- Published in:
- ChemMedChem, 2021, v. 16, n. 11, p. 1798, doi. 10.1002/cmdc.202001011
- By:
- Publication type:
- Article
Corrigendum: Interleukin-2-Inducible T-Cell Kinase Deficiency—New Patients, New Insight?.
- Published in:
- Frontiers in Immunology, 2018, p. N.PAG, doi. 10.3389/fimmu.2018.02197
- By:
- Publication type:
- Article
Interleukin-2-Inducible T-Cell Kinase Deficiency--New Patients, New Insight?
- Published in:
- Frontiers in Immunology, 2018, p. 1, doi. 10.3389/fimmu.2018.00979
- By:
- Publication type:
- Article
Hydroxamic Acids Immobilized on Resins (HAIRs): Synthesis of Dual‐Targeting HDAC Inhibitors and HDAC Degraders (PROTACs).
- Published in:
- Angewandte Chemie International Edition, 2020, v. 59, n. 50, p. 22494, doi. 10.1002/anie.202006725
- By:
- Publication type:
- Article
Unleashing T cell anti-tumor immunity: new potential for 5-Nonloxytryptamine as an agent mediating MHC-I upregulation in tumors.
- Published in:
- Molecular Cancer, 2023, v. 22, n. 1, p. 1, doi. 10.1186/s12943-023-01833-8
- By:
- Publication type:
- Article
Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL.
- Published in:
- Cancer Immunology, Immunotherapy, 2021, v. 70, n. 12, p. 3701, doi. 10.1007/s00262-021-03008-0
- By:
- Publication type:
- Article
Senescent Tumor CD8 + T Cells: Mechanisms of Induction and Challenges to Immunotherapy.
- Published in:
- Cancers, 2020, v. 12, n. 10, p. 2828, doi. 10.3390/cancers12102828
- By:
- Publication type:
- Article
Hydroxamic Acids Immobilized on Resins (HAIRs): Synthese von Dual‐Target‐HDAC‐Inhibitoren und HDAC‐PROTACs.
- Published in:
- Angewandte Chemie, 2020, v. 132, n. 50, p. 22681, doi. 10.1002/ange.202006725
- By:
- Publication type:
- Article
Synthesis, Antiplasmodial, and Antileukemia Activity of Dihydroartemisinin–HDAC Inhibitor Hybrids as Multitarget Drugs.
- Published in:
- Pharmaceuticals (14248247), 2022, v. 15, n. 3, p. 333, doi. 10.3390/ph15030333
- By:
- Publication type:
- Article
Deep Transfer Learning Approach for Automatic Recognition of Drug Toxicity and Inhibition of SARS-CoV-2.
- Published in:
- Viruses (1999-4915), 2021, v. 13, n. 4, p. 610, doi. 10.3390/v13040610
- By:
- Publication type:
- Article
Lmo2 expression defines tumor cell identity during T‐cell leukemogenesis.
- Published in:
- EMBO Journal, 2018, v. 37, n. 14, p. 1, doi. 10.15252/embj.201798783
- By:
- Publication type:
- Article